Drug Profile
Research programme: mitochondrial disorders therapeutics - Mitopharm/Abliva
Alternative Names: Ciclosporin derivatives - Abliva; mPT inhibitors; NICAM; NVP 016; NVP 017Latest Information Update: 05 Jun 2020
Price :
$50
*
At a glance
- Originator Mitopharm Limited; NeuroVive Pharmaceutical
- Developer Abliva; Mitopharm Limited
- Class Antineoplastics; Cardiovascular therapies; Ciclosporins; Obesity therapies
- Mechanism of Action Cyclophilin D inhibitors; Mitochondrial permeability transition pore inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute heart failure; Cancer; Obesity; Stroke
Most Recent Events
- 28 May 2020 NeuroVive Pharmaceutical is now called Abliva
- 21 Feb 2019 NeuroVive Pharmaceutical enters into an exclusive agreement with Oroboros Instruments to license and supply two of its first generation of succinate/malonate prodrugs originating from NVP 015 program
- 04 Nov 2017 No recent reports of development identified for research development in Acute-heart-failure in Sweden (IV)